Cetuximab is a chimeric monoclonal antibody that has revolutionized the treatment of metastatic colorectal cancer. Knowledge of the mechanisms that underlie its effectiveness, as well as the primary and secondary resistance mechanisms, have led to important developments in the understanding of cetuximab biology. In light of knowledge gained from recent trials, the efficacy of cetuximab has been clearly demonstrated to depend upon RAS mutational status, moreover cetuximab should only be used in a subset of patients who may benefit. In this article, we critically review clinical and pharmacogenetic issues of cetuximab, focusing on the cost-effectiveness involved with the use of the drug.
Silvestris, N., Vincenzi, B., Brunetti, A.E., Loupakis, F., Dell'Aquila, E., Russo, A., et al. (2014). Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. PHARMACOGENOMICS, 15(13), 1701-1715 [10.2217/pgs.14.124].
Pharmacogenomics of cetuximab in metastatic colorectal carcinoma
Russo, Antonio;Santini, Daniele
2014-01-01
Abstract
Cetuximab is a chimeric monoclonal antibody that has revolutionized the treatment of metastatic colorectal cancer. Knowledge of the mechanisms that underlie its effectiveness, as well as the primary and secondary resistance mechanisms, have led to important developments in the understanding of cetuximab biology. In light of knowledge gained from recent trials, the efficacy of cetuximab has been clearly demonstrated to depend upon RAS mutational status, moreover cetuximab should only be used in a subset of patients who may benefit. In this article, we critically review clinical and pharmacogenetic issues of cetuximab, focusing on the cost-effectiveness involved with the use of the drug.File | Dimensione | Formato | |
---|---|---|---|
Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.pdf
accesso aperto
Dimensione
6.16 MB
Formato
Adobe PDF
|
6.16 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.